|Ms. Adelene Q. Perkins||Chairman and Chief Exec. Officer||850.97k||N/A||57|
|Dr. Lawrence E. Bloch M.D., J.D.||Pres, Principal Accounting Officer and Treasurer||541.66k||N/A||51|
|Mr. Seth A. Tasker J.D.||VP, Gen. Counsel & Sec.||354.18k||N/A||38|
|Ms. Melissa Hackel||VP of Fin.||N/A||N/A||N/A|
|Dr. Jeffery L. Kutok M.D., Ph.D.||Chief Scientific Officer and Sr. VP||N/A||N/A||50|
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Its lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma) is in Phase 1 clinical study. The company has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Infinity Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.